Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
about
Nelarabine in the treatment of refractory T-cell malignanciesProfile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemiaTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureBeyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaActivating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.Childhood acute lymphoblastic leukemia: Integrating genomics into therapyChimeric antigen receptor T cells for sustained remissions in leukemiaNelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupNelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemiaLow expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patientsNelarabine in the treatment of refractory T-cell malignant diseases.Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Treatment of pediatric acute lymphoblastic leukemia.Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.Advances in paediatric cancer treatmentUpdate on the therapy of highly aggressive non-Hodgkin's lymphoma.Nelarabine: efficacy in the treatment of clinical malignancies.Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.Clofarabine for the treatment of acute lymphoblastic leukemia.Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial EfficiencyTherapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Adult acute lymphoblastic leukemia: concepts and strategies.Educational paper. The development of new therapies for pediatric oncology.New nucleoside analogs for patients with hematological malignancies.New drug therapies in peripheral T-cell lymphoma.Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.
P2860
Q24569660-67EFDB01-E8D4-48B1-B853-20592E5B5D7CQ24633723-623DA6B4-7B31-4D87-8056-6C8BEF9B209DQ26746934-0B7F5634-CB82-4438-B272-1BE95F2CA9DBQ26781328-B4BB3210-C316-4B33-BC9E-628BDE668002Q27852067-74B51780-6C5F-4873-9360-12AB4E4619A4Q28080463-0D9F6348-949F-4FB2-B9C6-7A1C456A9E05Q29617588-11C8AA6E-E290-459C-BEB1-C3046B1E7886Q30240892-4FC2A2C8-8AFF-4992-AB50-A70DEB832726Q30243925-A8B0091E-E5C8-4F9B-B2E3-ED19141F89B3Q30300395-FFFB2EB0-2745-4D82-B9F0-8F8E2DCE8F79Q30417943-A275C75A-4C7D-4D93-A525-17B83B40F8E9Q33374461-62D5876F-7A36-485A-8B11-EF0712FFC192Q33711119-FDABA7C9-F25B-4596-9485-527DEECF51A5Q33916091-64D21B32-6F96-4FCD-BE0A-AF1B36D7BBBEQ34469099-4BA076B2-85D5-4998-A3B3-3844BD43D69CQ34559575-11D5BEE8-0812-436E-9C75-6199270E91D9Q34592646-8F4426A3-385E-4D08-8415-FFF96CFB7A1DQ34764504-4EDBE1D1-D632-4168-8E69-6B8B4380F15AQ35196702-4F184552-D24D-40F3-A91D-FEA536EFDE98Q35615374-B3C6BBEB-FDBB-47D8-858B-29A929586C5FQ35667279-5B06B9D8-9A6A-4964-8402-CBBD58FE73E9Q35989408-F9A85DB4-C887-44AA-AB1E-95BC46F0A801Q36508149-089A9B95-361E-4CE0-9BBD-9465E7742CF9Q36508630-80F89119-49B2-49DC-B48F-5968DF279D2BQ36521840-7F79F661-0EFA-408D-8B32-73D5BB8F38D1Q36572507-EA074380-D7C1-43F7-A584-949616C54A24Q36654341-77A3B3A2-3416-416D-B056-C39D7AC8A3E0Q36731404-F9C8AB22-2D57-487D-A805-43F48E55CE6CQ36758604-EA146BBA-F399-44A0-83E1-A7A813B6CED6Q36771221-D256658E-2063-4F16-89E1-9AA51793B2B7Q37048013-EA11D207-5C54-424A-8CE6-080EE090FBFDQ37271941-D3EFC10B-4872-44BB-9E7C-1EF7F407C79BQ37360025-BA7D329B-4EF1-406D-8D83-64C0E0519E37Q37424784-96C4B021-B6F1-4B77-BC01-E13B63A636FCQ37681450-9F99830E-3A55-4887-B550-52BAECD6852EQ37824438-1702DA1B-FA6D-4DBA-B263-A1F04595E17BQ37841589-0B0DFDEA-BF70-477F-8354-C1BC7C6E3243Q37854715-16592E22-F23A-4CF9-8770-2451625FBA98Q37932546-3F5DE602-0D53-4E30-8822-22ADCFF27BCBQ38033592-01E3D87D-9CF8-4A54-82FA-B5C0F53AB6E6
P2860
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase II study of nelarabine ( ...... the Children's Oncology Group.
@en
Phase II study of nelarabine
@nl
type
label
Phase II study of nelarabine ( ...... the Children's Oncology Group.
@en
Phase II study of nelarabine
@nl
prefLabel
Phase II study of nelarabine ( ...... the Children's Oncology Group.
@en
Phase II study of nelarabine
@nl
P2093
P356
P1476
Phase II study of nelarabine ( ...... the Children's Oncology Group.
@en
P2093
Amy Billett
Anthony Murgo
Children's Oncology Group
Greg Reaman
James Whitlock
Joanne Kurtzberg
Mark Bernstein
Mark Krailo
Meenakshi Devidas
Michael B Harris
P304
P356
10.1200/JCO.2005.03.426
P407
P577
2005-05-01T00:00:00Z